RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

Benzinga Newsdesk www.benzinga.com Negative 95.1%

Neg 95.1% Neu 0% Pos 0%

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.